The investigational drug lecanemab slowed clinical decline in participants with early-stage Alzheimer’s disease by 27% after 18 months of treatment compared with participants who received a placebo, a phase 3 clinical trial has reported.
The results of...
In October 2020, Yale President Peter Salovey announced a series of goals and objectives to promote a sense of belonging for all members of the university community. To meet those objectives, he created a series of university-wide initiatives that form...
Since 1924 Yale has housed its own glassblowing facility to accommodate the custom needs of its research scientists. Today, the Yale Glass Shop is led by glassblowers Daryl Smith and Preston Smith, a father-son team that applies their rare craft to...
As an undergraduate at the University of Cambridge in the late 1960s, anthropologist Dame Alison Richard spent a miserable summer in Panama trying to study monkeys. It rained constantly and poisonous snakes were easier to spot than the primates.
Then one...
In the latest edition of Humanitas, a column focused on the arts and humanities at Yale, a scholar of Native and Indigenous studies explores what the history of ice and coldness in Hawai’i reveals about imperialism and food sovereignty, two young...
This month, Insights & Outcomes turns its attention to a variety of subtle factors and influences that play a role in protein development, Tourette Syndrome, multiple sclerosis, and health care inequity.
As always, you can find more science and...